{
    "Trade/Device Name(s)": [
        "ARCHITECT Total Bilirubin"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K121985",
    "Predicate Device Reference 510(k) Number(s)": [
        "K060574"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CIG",
        "MQM"
    ],
    "Summary Letter Date": "March 14, 2019",
    "Summary Letter Received Date": "December 21, 2012",
    "Submission Date": "December 20, 2012",
    "Regulation Number(s)": [
        "21 CFR 862.1110"
    ],
    "Regulation Name(s)": [
        "Bilirubin Test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Total Bilirubin"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "ARCHITECT c8000 system"
    ],
    "Method(s)/Technology(ies)": [
        "Colorimetric chemical reaction",
        "Diazo reaction"
    ],
    "Methodologies": [
        "Quantitative analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for ARCHITECT Total Bilirubin assay for quantitative analysis of total bilirubin in human serum or plasma on the ARCHITECT c8000 system",
    "Indications for Use Summary": "Quantitation of total bilirubin in human serum or plasma for diagnosis and treatment of liver, hematological, and metabolic disorders, including hepatitis and gall bladder block; in neonates, aids in indicating risk of bilirubin encephalopathy (kernicterus)",
    "fda_folder": "Clinical Chemistry"
}